ARCHIVES

Control-Arm CML Patients In Phase III Gleevec Study Allowed To Switch.

This article is from The Cancer Letter archive.

Vol. 28 No. 04 | January 25, 2002

Download PDF Visit The Full Archive

Related Articles

Subcommittee chairman Critical Of DCR For Lack Of “Game Plan”

October 28, 1977

NRC considering “Escalated” Enforcement Action Against NIH

February 2, 1996

In Brief: NCI Tells Cooperative Groups To Submit applications For Extra Multimodality Funds

November 28, 1975

Chemo, Radiation Improves DFS In Head & Neck Cancer

May 28, 2004

In Brief: Most NCI Grants, Including Noncompeting And r01s, Will Take Cuts Of At Least 4 Percent; Paylines Set

January 22, 1982

NCI To End CIS Partnership Program In 2010.

December 5, 2008